Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 04 2022 - 1:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
Results of 22nd Annual
General Meeting
GlaxoSmithKline
plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm
on Wednesday 4 May 2022. Shareholders were able to join
virtually via Lumi, Zoom and in person at the meeting held at the
Sofitel Hotel in Terminal 5 Heathrow.
All
valid proxy votes (whether submitted electronically or in hard copy
form) were included in the poll taken at the meeting.
The table below shows the results of the poll on
all 28 resolutions. The full text of the resolutions is contained
in the Notice of AGM published on 28 March 2022, which is available
on GSK's website at www.gsk.com.
Resolution
|
Total votes for(1)(2)
|
%
|
Total votes against(2)
|
%
|
Total votes cast
|
Votes withheld(3)
|
1
|
Receive and adopt the 2021 Annual Report
|
3,524,582,633
|
99.01
|
35,137,552
|
0.99
|
3,559,720,185
|
11,843,164
|
2
|
Approve the Annual report on remuneration
|
3,240,737,115
|
91.05
|
318,510,405
|
8.95
|
3,559,247,520
|
12,317,062
|
3
|
Approve the Remuneration Policy
|
2,197,755,545
|
61.76
|
1,360,515,540
|
38.24
|
3,558,271,085
|
13,294,793
|
4
|
Election of Dr Anne Beal
|
3,546,443,179
|
99.55
|
16,055,842
|
0.45
|
3,562,499,021
|
9,042,781
|
5
|
Election of Dr Harry Dietz
|
3,545,845,271
|
99.54
|
16,469,238
|
0.46
|
3,562,314,509
|
9,224,475
|
6
|
Re-election of Sir Jonathan Symonds
|
3,482,374,837
|
97.76
|
79,898,313
|
2.24
|
3,562,273,150
|
9,274,730
|
7
|
Re-election of Dame Emma Walmsley
|
3,555,195,651
|
99.79
|
7,564,971
|
0.21
|
3,562,760,622
|
8,806,465
|
8
|
Re-election of Charles Bancroft
|
3,503,934,446
|
98.36
|
58,393,472
|
1.64
|
3,562,327,918
|
9,214,474
|
9
|
Re-election of Vindi Banga
|
3,483,288,426
|
97.79
|
78,881,291
|
2.21
|
3,562,169,717
|
9,373,841
|
10
|
Re-election of Dr Hal Barron
|
3,546,018,185
|
99.54
|
16,347,031
|
0.46
|
3,562,365,216
|
9,173,855
|
11
|
Re-election of Dr Vivienne Cox
|
3,531,865,048
|
99.14
|
30,474,324
|
0.86
|
3,562,339,372
|
9,204,548
|
12
|
Re-election of Lynn Elsenhans
|
3,476,281,291
|
97.58
|
86,142,909
|
2.42
|
3,562,424,200
|
9,118,541
|
13
|
Re-election of Dr Laurie Glimcher
|
3,556,622,114
|
99.84
|
5,547,225
|
0.16
|
3,562,169,339
|
9,375,696
|
14
|
Re-election of Dr Jesse Goodman
|
3,555,655,121
|
99.82
|
6,515,409
|
0.18
|
3,562,170,530
|
9,367,820
|
15
|
Re-election of Iain Mackay
|
3,551,784,186
|
99.71
|
10,432,989
|
0.29
|
3,562,217,175
|
9,333,434
|
16
|
Re-election of Urs Rohner
|
3,410,175,068
|
95.74
|
151,806,419
|
4.26
|
3,561,981,487
|
9,561,680
|
17
|
Re-appointment of the auditor
|
3,557,280,686
|
99.84
|
5,797,033
|
0.16
|
3,563,077,719
|
8,481,780
|
18
|
Remuneration of the auditor
|
3,555,233,064
|
99.86
|
5,000,395
|
0.14
|
3,560,233,459
|
11,338,880
|
19
|
Authority for the company to make donations to political
organisations and incur political expenditure
|
3,493,409,287
|
98.64
|
48,161,797
|
1.36
|
3,541,571,084
|
30,003,446
|
20
|
Authority to allot shares
|
3,430,993,149
|
96.35
|
130,127,471
|
3.65
|
3,561,120,620
|
10,593,875
|
21
|
Disapplication of pre-emption rights - general
power(4)
|
3,460,375,320
|
97.24
|
98,220,644
|
2.76
|
3,558,595,964
|
12,963,416
|
22
|
Disapplication of pre-emption rights - in connection with an
acquisition or specified capital investment(4)
|
3,404,168,390
|
95.65
|
154,942,194
|
4.35
|
3,559,110,584
|
12,448,092
|
23
|
Authority for the company to purchase its own
shares(4)
|
3,517,497,794
|
98.79
|
43,085,674
|
1.21
|
3,560,583,468
|
10,990,502
|
24
|
Exemption from statement of senior statutory auditor's
name
|
3,523,554,816
|
99.59
|
14,359,955
|
0.41
|
3,537,914,771
|
33,655,391
|
25
|
Authority for reduced notice of a general meeting other than an
AGM(4)
|
3,331,432,180
|
93.62
|
227,176,994
|
6.38
|
3,558,609,174
|
12,950,914
|
26
|
Approve the Share Save Plan 2022
|
3,508,449,940
|
98.62
|
49,235,709
|
1.38
|
3,557,685,649
|
13,896,262
|
27
|
Approve the Share Reward Plan 2022
|
3,516,666,377
|
98.86
|
40,690,090
|
1.14
|
3,557,356,467
|
14,160,284
|
28
|
Approve the adoption of new Articles of
Association(4)
|
3,549,030,121
|
99.80
|
6,964,097
|
0.20
|
3,555,994,218
|
15,501,889
|
Resolution 3 - Approval of the Remuneration Policy
The
Company was pleased that the new remuneration policy was supported
in a vote at today's Annual General Meeting. It also notes
that a significant minority were not able to support the new policy
at this time. The Company undertook an in-depth consultation
process with the majority of its largest shareholders in developing
the revised policy and will continue to engage to ensure it fully
understands the views of all shareholders on these matters, and to
continue to explain the rationale for the changes.
Notes:
(1) The
"for" votes include those giving the Chair discretion. In line with
the notification issued to American Depositary Receipt (ADR)
holders last year, GSK did not instruct its ADR Depositary to vote
any unvoted ADRs in respect of the AGM resolutions.
(2)
Votes "for" and "against" are expressed as a percentage of the
total votes cast.
(3)
A vote withheld is not a vote in law and is not counted in the
calculation of the proportion of votes "for" or "against" a
resolution.
(4)
Indicates Special Resolutions requiring a 75%
majority.
The following table provides further information on participation
in the AGM:
|
GSK's
Twenty second
AGM
(Hybrid meeting)
(2022)
|
GSK's
Twenty first
AGM
(Virtual meeting)
(2021)
|
Issued share capital (excluding Treasury Shares)
|
5,083,974,547
|
5,031,444,276
|
Total votes cast and votes withheld lodged as a % of GSK's issued
share capital (excluding Treasury Shares)
|
70.25%
|
70.11%
|
Total shareholder population
|
89,764
|
100,906
|
Total number of proxies lodged
|
5,343
|
6,089
|
Number of shareholders in attendance
|
93 in person
68 participated virtually
|
142 participated virtually
|
% of shareholders who lodged proxies
|
5.95%
|
6.03%
|
The above poll results will shortly be available
on the company's website at www.gsk.com.
In accordance with Listing Rule 9.6.2, a copy of the resolutions,
other than those concerning ordinary business, will be submitted to
the UK Listing Authority and will in due course be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
Company Secretary
4 May 2022
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
04, 2022
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024